Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'phase dose'
phase dose published presentations and documents on DocSlides.
Phase I and Phase II trial design in
by tatiana-dople
oncology. Shu-Fang Hsu Schmitz. University of Ber...
Estimating the dose-toxicity curve from completed Phase I studies
by isla
Alexia Iasonos, . Irina Ostrovnaya. Department of ...
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study
by chiquity
to . Determine the Maximum Tolerated Dose for the ...
MErCuRIC1: A phase 1 Multi-Centre Study of
by badra
Crizotinib. (. cMET. inhibitor) Combined . with ...
Phase I Trials: Statistical Design Considerations
by natalia-silvester
Phase I Trials: Statistical Design Consideratio...
Phase I Trials: Statistical Design Considerations
by marina-yarberry
. Hong Li. (Acknowledgement: some slides from R...
Phase I Trial Designs Jud Blatchford, PhD
by faustina-dinatale
Colorado School of Public Health. January 30. th....
Designing Phase I Trials With Targeted Agents:
by giovanna-bartolotta
Challenging Tradition. Chia-Chi (Josh) Lin, MD, P...
Phase I trials: A New era in
by mitsue-stanley
OnCology. drug development. Jan 22, 2015. Method...
Abstract #323 : An open-label, dose escalation, Phase I/II study to assess safety, tolerability, im
by caitlin
J. Bennouna. 1. , A. Sibille. 2. , C. Debruyne. 3....
Phase IB trial of carboxyamidotriazole
by cheryl-pisano
orotate (CTO) and radiotherapy . with concurrent...
Wntresearch
by alexa-scheidler
General Assembly 2015. 2. Approximately. 55 000 ...
Adapting for Success: The Genesis of Adaptive Designs
by alida-meadow
Andy Grieve. SVP Clinical Trials Methodology, . I...
Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic Ewing
by alexa-scheidler
Phase I Study of Olaparib and Temozolomide, in pa...
Design considerations for drug development in the era of immuno-oncology
by isabella
Elizabeth Garrett-Mayer, PhD. Director, Division o...
Posters: 1 Minute Previews
by elina
C. areers . and. A. cademic. L. iaison . C. ommitt...
Trial Design Issues for Phase II Trials
by audrey
Guide to Two-Stage . IIa. Designs and . IIa. /IIb...
DEVELOPMENT OF RV3 ROTAVIRUS VACCINE
by williams
Mahendra. . Suhardono. Production Director. 11. t...
Date | Presenter
by karlyn-bohler
Case Example: . Bayesian . Adaptive, Dose-Finding...
Goals
by phoebe-click
Store the results of Patient Organ Dose calculati...
Date | Presenter
by luanne-stotts
Case Example: . Bayesian . Adaptive, Dose-Finding...
An APC activator (IMP321 or LAG-3Ig) combined with anti-PD
by yoshiko-marsland
Frédéric Triebel, M.D., PhD. , Prima Biomed Ltd...
How to Find and Participate in a GIST clinical trial
by ellena-manuel
(aka---how to know where to look and who to call)...
PAG Manual Revision
by briana-ranney
Update and Next Steps. November 7, 2016. Presente...
Sudanese Human Reproduction & Embryology Society
by liane-varnes
Assessment and treatment for people with. fertili...
Measles Rubella Meeting
by test
22nd June, 2016. Dr. Craig Burgess, JSI. Multi D...
Update on Treatment of Myasthenia Gravis
by conchita-marotz
KUMC Neurology Grand Rounds. 07/29/2016. Richard...
Safety Considerations in Phase 1 Trials
by stefany-barnette
Sumathi Nambiar MD MPH. Director. Division of Ant...
A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and
by scoopulachanel
Myeloma. 1. Safety and Efficacy of Daratumumab wit...
Please refer to CCMB Formulary for Crit
by patricia
ADULT Updated: October 2 8 , 20 20 eria for Use Pa...
Treatment of amenorrhea A.Amouzegar
by julia
Research Institute for Endocrine Science. 13 . Aba...
PHARMACOKINETICS DR NARENDRA KUMAR
by anderson
Pharmacokinetics of drugs . (ADME). . Are studies...
Cell Lung Cancer
by eloise
Non - small Locally Advanced Daniel W. Golden MD,...
1 Endothelium: Vasculoprotective
by wilson
, Stabilizes BBB integrity. Neurons:. Direct Neur...
Clinical Pharmacology 2:
by myesha-ticknor
Clinical Pharmacology Considerations During Phase...
Clinical Trial Protocol & Amendments
by liane-varnes
William Petros, PharmD, FCCP. Professor, Schools ...
Bruix J et al. Lancet 2017;389(10064):56-66.
by kittie-lecroy
Regorafenib. 160 mg/d. (n = 379). Placebo. (n = ...
Long Acting ART for Treatment and
by tatyana-admore
PrEP. Anton Pozniak . MD FRCP. Consultant Physici...
Phase IB Trial of Carboxyamidotriazole Orotate
by myesha-ticknor
(CTO) and . Temozolomide. for Recurrent Malignan...
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells Incorporating a Chlorotoxin
by beatrice
Tumor-targeting Domain for Patients with MMP2+ Rec...
Load More...
